{"schema_version":"secwatch.filing_event.v1","accession":"0001773751-25-000248","form_type":"8-K","ticker":"HIMS","cik":"0001773751","company_name":"Hims & Hers Health, Inc.","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.947083+00:00","generated_at":"2026-05-17T21:32:26.792213+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Hims & Hers Q2 rev $545M (+73%), net income $42.5M, reaffirms FY25","bullets":["Revenue $544.8M (+73% YoY); net income $42.5M (vs $13.3M); Adj EBITDA $82.2M (vs $39.3M).","Subscribers 2.44M (+31% YoY); monthly online revenue per subscriber $74 (+30% YoY).","Gross margin 76% (down ~500 bps YoY); free cash flow -$69.4M (vs +$47.6M prior year).","FY25 guidance reaffirmed: revenue $2.3-2.4B and Adj EBITDA $295-335M.","Acquired ZAVA Global (European digital health); expects $50M+ revenue from ZAVA in H2 at positive EBITDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001773751-25-000248","json":"https://secwatch.observer/filing/0001773751-25-000248.json","markdown":"https://secwatch.observer/filing/0001773751-25-000248.md","text":"https://secwatch.observer/filing/0001773751-25-000248.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1773751/000177375125000248/0001773751-25-000248-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1773751/000177375125000248/hims-20250804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:32:26.792213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}